Comparison · NCT04859517-04ecc808
ADG20 IM - Cohort B vs Placebo IM - Cohort B: Percentage of Participants With at Least 1 COVID-19 Related Medically Attended Outpatient Visit (PrEP)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. ADG20 IM - Cohort B vs Placebo IM - Cohort B: Percentage of Participants With at Least 1 COVID-19 Related Medically Attended Outpatient Visit (PrEP). Trial comparisons, record NCT04859517-04ecc808. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04859517-04ecc808
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0833 | 0.0149 | 0.354 | wilson | |
| Risk in group 2 | 0.15 | 0.0706 | 0.291 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0667 | -0.223 | 0.215 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.556 | 0.074 | 4.17 | log | |
| Odds ratio, group 1 over group 2 | 0.515 | 0.0558 | 4.76 | log | |
| Number needed to treat, for one fewer participant with the outcome on ADG20 IM - Cohort B than on Placebo IM - Cohort B | 15 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | ADG20 IM - Cohort B | ADG20 IM - Cohort B is a pre-exposure prophylaxis (PrEP) arm where participants with no known history of SARS-CoV-2 infection and no known recent exposure to SARS-CoV-2 but whose circumstances put them at increased risk of exposure to SARS-CoV-2 were administered a single dose of ADG20 IM on Day 1. | 1 | 12 | OG000 |
| Group 2 | Placebo IM - Cohort B | Placebo IM - Cohort B is a pre-exposure prophylaxis (PrEP) arm where participants with no known history of SARS-CoV-2 infection and no known recent exposure to SARS-CoV-2 but whose circumstances put them at increased risk of exposure to SARS-CoV-2 were administered a single dose of placebo IM on Day 1. | 6 | 40 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Percentage of Participants With at Least 1 COVID-19 Related Medically Attended Outpatient Visit (PrEP)
- Description
Physician office, telemedicine, emergency room or urgent care center visits in participants with RT-PCR confirmed symptomatic COVID-19, defined as having a central RT-PCR-confirmed SARS-CoV-2 infection with COVID-19 symptoms occurring within 14 days from the positive RT-PCR test sample collection, COVID-19-related hospitalization with a positive local or central SARS-CoV-2 test within 14 days, or all-cause death.
- Time frame
- Day 1 through 3 Months or emergence of Omicron (15-Dec-2021), whichever is earlier
- Population
Participants with RT-PCR confirmed symptomatic COVID-19 in the pre-Omicron modified Full Analysis Set (mFAS): participants without prior or current SARS-CoV-2 infection at baseline based on central tests (baseline RT-PCR-negative and seronegative) randomized on or prior to 30-Nov-2021, allowing participants to be followed a minimum of 2 weeks through 15-Dec-2021 when Omicron became the predominant variant.
Source ClinicalTrials.gov
Trial
- Title
- Evaluation of ADG20 for the Prevention of COVID-19
- NCT number
- NCT04859517
- Phases
- PHASE2, PHASE3
- Conditions
- COVID-19
- Interventions
- ADG20, Placebo
- Lead sponsor
- Invivyd, Inc.
- Results first posted
- 2024-08-20
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04859517?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04859517-04ecc808